Drug Stock Reverses from Record Highs Despite Blowout Earnings

Eli Lilly's top-line beat is being dragged down by broad market headwinds

Digital Content Manager
Jan 29, 2021 at 3:04 PM
facebook twitter linkedin

The shares of Eli Lilly And Co (NYSE:LLY) are down 2.1% at $205.80 this afternoon -- likely due to some broad-market headwinds -- despite earlier surging to an all-time high of $218. The pharmaceutical giant reported better-than-expected fourth-quarter earnings of $1.42 per share this morning, as well as a revenue beat. The firm attributed the strong results to a 41.5% profit rise, thanks to higher demand for its diabetes drugs and the success of its Covid-19 antibody treatment. 

The security has been tearing up the charts since November, bouncing off its 20-day moving average and forming a channel of higher highs. Several bull gaps helped shares to today's peak, which is nearly double the equity's March lows. Year-over-year, LLY is up 44.4%.

LLY 20 Day

Analysts were overwhelmingly optimistic toward Eli Lilly stock coming into today, with nine of the 12 in coverage sporting a "strong buy" rating, while only three called it a tepid "hold." Meanwhile, the 12-month consensus target price of $201.63 is a 2% discount to current levels. 

The options pits lean bullish too, with an appetite for calls. This is per the security's 50-day call/put volume ratio of 3.44 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands higher than 95% of readings from the past year. This means calls are being picked up at a quicker-than-usual clip.

It looks like now is the time to take advantage of LLY's next move with options, after a post-earnings volatility crush. The equity's Schaeffer's Volatility Index (SVI) of 35% sits in the relatively low 28th percentile of its annual range, indicating options players are pricing in low volatility expectations at the moment.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!



Special Offers from Schaeffer's Trading Partners